RSH
Director Trades
| Date | Director | Value |
|---|
Company News
Respiri increases patient enrolments, revenue and conversion rates with streamlined onboarding system
Healthcare company Respiri (ASX: RSH) delivered strong growth in patient enrolments during the three months to the end of September across its chronic care management, remote patient monitoring, principal care management and transitional care management programs. A total of 2,435 individuals joined the programs, representing a 71% increase on the June quarter, attributed to a […]
Weekly wrap: shares rise to a record high on mining optimism
Australian shares just managed to seal a record closing high on Friday, with a strong rally in mining shares managing to offset losses in almost every other sector. By the close of trade, the ASX 200 was up a slim 8.5 points or 0.1% to 8212.2 points, with the index closing just above flat for […]
Respiri partners with Hawaiian care facilities in remote patient monitoring deal
Medical technology specialist Respiri (ASX: RSH) has once again displayed the diversity of its business offering by reaching agreements to provide remote nursing support to care facilities in Hawaii. The company has entered into two individual remote patient monitoring (RPM) agreements with Liliha and The Care Centre of Honolulu skilled nursing facilities (SNF) in deals […]
Respiri raises $1.5m to fast-track wheezo commercialisation in multi-billion-dollar US market
Health technology company Respiri (ASX: RSH) has unveiled a A$1.5 million capital raising as it fast-tracks its expansion through the US respiratory health market, which is forecast to be worth US$85 billion by 2026. The funds will be used to accelerate Respiri’s roll-out strategy of its Food and Drug Administration approved wheezo device and software […]
Respiri signs EAS Advisors to accelerate US market expansion
Asthma management specialist Respiri (ASX: RSH) has signed a deal with US boutique firm EAS Advisors LLC to accelerate its expansion into the North American market. Respiri, which develops solutions to improve the management of chronic and costly respiratory disorders, made its US market debut in December through select remote patient monitoring (RPM) partner companies, […]
Respiri launches first reimbursed remote patient asthma monitoring program in US
Respiratory health management specialist Respiri (ASX: RSH) has launched its first reimbursed remote patient monitoring (RPM) pilot program involving flagship product wheezo at the Children’s Hospital of Michigan in the United States. The program was secured with partner company Access Telehealth and will provide a full RPM solution, including patient engagement, for a select group […]
Respiri launches telehealth and remote patient respiratory management program in Australia
Respiratory health technology company Respiri (ASX: RSH) is trialling a telehealth and remote patient management program in Australia that will also form the basis of the model for the US reimbursement market. Led by leading respiratory physician Dr Kevin Chan, the program will bring together the treating respiratory specialist, primary care provider, Respiri’s wheezo asthma […]
Respiri makes strategic appointments to facilitate UK wheezo launch
Days after obtaining Food and Drug Administration approval for sales of its wheezo device in the US, Respiri (ASX: RSH) has progressed its international expansion plans with strategic adviser appointments to assist with preparing a UK market launch in the final quarter of this year. Dr Andrew Weekes and Dr Mark Levy have now joined […]
Respiri to sell wheezo device and technology in the United States after securing FDA approval
Wheezo device and app technology developer, Respiri (ASX: RSH) has received the greenlight from the United States Food and Drug Administration (FDA) to market and sell the technology as a class II medical device in the country. The regulatory approval enables wheezo to be sold OTC (over-the-counter) to patients with or without a prescription. Similar […]
Respiri and Pharmacy Catalyst to begin wheezo in-pharmacy asthma patient program next month
Respiratory health focused Respiri (ASX: RSH) has bedded-in support for its wheezo device and technology after Pharmacy Platform member Pharmacy Catalyst confirmed it will begin the wheezo in-pharmacy asthma patient program next month. Pharmacy Catalyst offers its 350 members professional service and education programs and is committed to community engagement with a patient-centric focus. Under […]
Company Videos
No videos found.